UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010992
Receipt number R000012814
Scientific Title Observational study on late effects and quality of life (QOL) in long-term survivors after allogeneic hematopoietic stem cell transplantation.
Date of disclosure of the study information 2013/06/19
Last modified on 2021/12/24 09:11:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational study on late effects and quality of life (QOL) in long-term survivors after allogeneic hematopoietic stem cell transplantation.

Acronym

Observational study on LTFU

Scientific Title

Observational study on late effects and quality of life (QOL) in long-term survivors after allogeneic hematopoietic stem cell transplantation.

Scientific Title:Acronym

Observational study on LTFU

Region

Japan


Condition

Condition

Hematopoietic stem cell trans-
plantation targeted diseases such as hematological diseases

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To prevent, diagnose, and treat early organ dysfunction and late effects after transplantation by analyzing incidence and risk factors of them and to improve QOL in long-term survivors with allogeneic hematopoietic stem cell transplantation.

Basic objectives2

Others

Basic objectives -Others

QOL

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

(1)Incidence and risk factors of organ dysfunction and late effects in long-term survivors after transplantation.
(2)Changes of QOL in long-term survivors after transplantation.
(3) Influence of organ dysfunction and late effects on QOL and life in patients after transplantation.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1)Patients who were first transplanted from January 2010.(Patients past of autologous transplantation history in is possible registration, autologous transplantation does not count.)
(2)Patients who survived for 150 days and above after last transplantation without relapse at study.
(3)Patients who aged 20 or above at transplantation.
(4)Patients who were accounted for this study in detail and signed a written informed consents.

Key exclusion criteria

(1) Patients who were unable to read,
understand, or reply to FACT-BMT, SF-36, and the questionnaire about life and social environment.
(2) Patients who are disqualified by
their attending physician.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Makoto
Middle name
Last name Murata

Organization

Nagoya University Hospital

Division name

Department of Hematology

Zip code

466-8550

Address

65 Tsurumai-cho, Showa-ku, Nagoya, 466-0065, Japan

TEL

052-744-2145

Email

mmurata@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Murata

Organization

Nagoya University Hospital

Division name

Department of Hematology

Zip code

466-8550

Address

65 Tsurumai-cho, Showa-ku, Nagoya, 466-0065, Japan

TEL

052-744-2145

Homepage URL


Email

mmurata@med.nagoya-u.ac.jp


Sponsor or person

Institute

Reserch group for LTFU

Institute

Department

Personal name



Funding Source

Organization

Nagoya BMT Group

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya University

Address

65 Tsurumai, Showa, Nagoya

Tel

052-744-2423

Email

ethics@med.nagoya-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 06 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 06 Month 04 Day

Date of IRB

2013 Year 05 Month 13 Day

Anticipated trial start date

2013 Year 06 Month 05 Day

Last follow-up date

2017 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

multicenter, observational study


Management information

Registered date

2013 Year 06 Month 18 Day

Last modified on

2021 Year 12 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012814


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name